Spring til...

  • Hovedindhold
  • Indholdsfortegnelse
  • Sidefod
  • Dansk da
Scientific article 26. SEP 2018

Cause-specific mortality in patients with psoriasis and psoriatic arthritis

Authors:

  • Lars Skov Henriksen
  • S.f. Thomsen
  • L.e. Kristensen
  • R. Dodge
  • M.s. Hedegaard
  • J. Kjellberg
Download Hent den videnskabelige artikel
Download Hent den videnskabelige artikel
BackgroundThere are limited data regarding causes of mortality in patients with psoriasis or psoriatic arthritis (PsA).ObjectivesThis retrospective cohort study evaluated the risk and leading causes of mortality in patients with psoriasis or PsA.
MethodsIndividuals with a hospital‐based diagnosis of PsA or psoriasis were identified using the Danish National Patient Registry. Matched control individuals were identified from the general population. The main outcome measures were risk of death and cause‐specific mortality in patients with psoriasis or PsA.
ResultsDeath rates per 1000 patient‐years (with 95% confidence intervals) vs. controls were 22·3 (19·7–24·9) vs. 13·9 (11·8–16·0) for patients with psoriasis and 10·8 (8·9–12·8) vs. 11·6 (9·6–13·6) for patients with PsA. Survival, according to stratified hazard ratios (HRs), was significantly lower in patients with psoriasis than in controls (HR 1·74, P < 0·001), but not in patients with PsA (HR 1·06, P = 0·19). Significantly increased risk of death was observed in patients with psoriasis vs. controls due to a number of causes; the highest risks were observed for diseases of the digestive system; endocrine, nutritional and metabolic diseases; and certain infectious and parasitic diseases (HRs 3·61, 3·02 and 2·71, respectively). In patients with PsA, increased mortality was observed only for certain infectious and parasitic diseases (HR 2·80) and diseases of the respiratory system (HR 1·46). Patients with psoriasis died at a younger age than controls (mean age 71·0 vs. 74·5 years, P < 0·001).
ConclusionsPatients with severe psoriasis have increased mortality risk compared with matched controls, due to a number of causes. Evidence to support an increased risk for patients with PsA was less convincing.

Authors

  • Lars Skov HenriksenS.f. ThomsenL.e. KristensenR. DodgeM.s. HedegaardJ. Kjellberg

About this publication

  • Published in

    British Journal of Dermatology
VIVE – The Danish Centre for Social Science Research provides knowledge that contributes to developing the welfare society and strengthening quality development, efficiency enhancement and governance in the public sector, both in municipalities, regions and nationally.
Tel: +45 44 45 55 00
E-mail: vive@vive.dk
EAN: 5798000354845
CVR: 23 15 51 17